https://theedgemalaysia.com/node/703916

Genting’s target price could be raised to as high as RM9.40 under a blue sky scenario, where HMTM is approved and TauRx is valued at US$15 billion (RM70.3 billion) without discount, the research house added.

TP RM9.40

We are pleased to confirm receipt of investigative new drug (IND) approval from the National Medical Products Administration (NMPA) in China for study TRx-237-801. dMed-Clinipace, a global CRO based in Shanghai, has been selected as the research partner for this study.
We estimate that 60% of the global burden of AD is in Asian countries compared with only 12% in Europe and US combined.

Submitted for approval. Once approved no problem breaking RM7.

Eli Lilly got any thing to do with TauRX?

Cannot do anything. Just wait until the durian drop.

When can get official approval ? soon ?

Afternoon closing price very important.

https://theedgemalaysia.com/node/703916

KUALA LUMPUR (March 8): TauRx Pharmaceuticals Ltd, the 20%-owned associate of Genting Bhd, said new data show that its trial drug to combat Alzheimer's disease has “sustained benefits” across the disease spectrum from early to moderate dementia.

The new 24-month data from the third phase of the so-called LUCIDITY trial of hydromethylthionine mesylate (HMTM) showed “significantly” reduced disease progression in participants, TauRx said in a statement following a presentation at a conference in Portugal.

Genting’s target price could be raised to as high as RM9.40 under a blue sky scenario, where HMTM is approved and TauRx is valued at US$15 billion (RM70.3 billion) without discount, Maybank said.

https://www.nst.com.my/amp/business/2022/06/804468/genting-set-early-monetisation-associate-firm-taurx

RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin.

KUALA LUMPUR: Merger and acquisition (M&A) of Genting Bhd's 20.3 per cent-owned research and development (R&D) associate TauRx Pharmaceuticals Ltd could allow for faster monetisation versus initial public offering (IPO), RHB Research said.
The firm said while Genting did not comment on its strategy with regards to its TauRx stake, any option of value realisation or monetisation was definitely a positive after having invested in the firm since November 2012.
"For TauRx to IPO, it would need to first commercialise its lead investigative oral drug, HMTM, in 2023 and undertake listing in 2024 or later.

"Conversely, we think M&A or in-licensing agreements may allow for earlier monetisation of Genting's stake, given that large pharmaceutical firms may have M&A interest in TauRx in order to possess the world's only effective Alzheimer's treatment.

"As a plus, M&A could allow TauRx to leverage on such firms' resources to expedite HMTM speed to market," it said in a note today. RHB Research said the HMTM drug would need to undergo 12 months of open-label trials – it could seek regulatory approvals for this Alzheimer's drug before the trial's conclusion.

RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin.
It could also fetch an upside of RM3.47-RM13.88 a share share based on 10x price to earnings ratio (P/E) on our base and bull cases for FY24 earnings," it said.

RHB said this could translates to hypothetical target price of RM9.84-RM20.25 for Genting.

Genting always got disappointment and surprises.

Don't give up 愛拼才會贏.

Genting Berhad
TauRX tomorrow presentation day.
愛拼才會贏

Interesting.
Afternoon not sure got magic show ?

https://www.businesstoday.com.my/2024/03/05/all-eyes-on-gentings-taurx-alzheimer-phase-3-trial/

On 7 Mar 2024, Genting Berhad’s 20%-owned TauRx will present full results from its Phase 3 LUCIDITY trial of HMTM that is designed to combat Alzheimer’s disease. It has initiated regulatory engagement in the United Kingdom and the United States for product approval.

Under a ‘blue sky’ scenario where HMTM is approved and TauRx is valued at USD15b with no discount ascribed to it, Maybank IB says GENT TP could be raised to MYR9.40. As for now the house estimates MYR5.73 TP unchanged but encourages investors to BUY now to position ahead.

AngTayKor
Your update is very important and useful. Please continue.

I would have sold all my Genting long time ago.
It's because of TauRX, I am still holding until now.
Hopeless hope. Very disappointed.

Maybank IB advises investors to look at Genting given its involvement in life sciences

NST Tue, Mar 05, 2024 12:12pm - 51 minutes .....latest news just came in.

Q3 result not yet out ?

AngTayKor...... thanks

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.

Tomorrow.

1) sell that land in US fast.
2) IPO Las Vegas hotels and Casino.
3) TauRX launching.
Genting management please work harder and faster. Wake up.

Too many containers only a few covers. Hoping for the best.

Kindly be advised of the following :

1) The above Company's securities will be traded and quoted "Ex - Dividend” as from: 20 Mar 2024
2) The last date of lodgment : 21 Mar 2024
3) Date Payable : 19 Apr 2024

Why selling like the end of the world.
The company is still making good profit and can afford to pay dividend.

https://www.thestar.com.my/business/business-news/2024/03/01/genting039s-outlook-boosted-by-multiple-factors

????????

If you are not happy with the results, just sell. To me the results is reasonable. Will wait for TauRX progress.

GenM dividend 9 cents

Check bursa announcement

GenM results out already. Quite good 👍

Really pity those got force selling. Never learn. No money don't buy and don't play contra.

Based on total Q1 to Q3 2023 results. I think total year 2023 profit should be higher than 2022.
Q4 2023 maybe lower than Q3 20238 but still showing profit.

Consolidate all in Sky casino with latest technology and machine. Each old machines need to pay high gambling tax.

Still no results.

Maybe LKT wanted to push the price down and accumulate more before TauRX announcement.

@AngTayKor...when do you think TauRX could get approval ? In a year or more than 2 years

When GenB results?

Just wait for Q4 results. Wait until March 2024 TauRX presentation.
Then only decide buy or sell.

Anyone got GenB results please immediately share.

We are now playing Blackjack casino game.
LKT is the Banker and we are the players.
Picture, Picture, Picture

GenP and GenB result when ? both today ?

Monday ???????????
See how....maybe U Turn.

Today everyone follow selling ?
Tomorrow up everyone chasing without thinking.
the game never end.

Genting Malaysia share price still ok.
Genting Berhad force selling. If you don't have money to pick-up, please don't buy.
It is very painful under force selling by broker.

March 2024 TauRX presentation is just a dream. May the dream come true.

Those bought recently with high trading volume got burn badly.
Why selling at a loss. Cutting loss is not a good habits. You will never win.

WTF - LKT

Today after 5pm we will know Genting Singapore result.

Forget about history.
Looking forward to latest result. Tomorrow Genting Singapore result very important.

Apa lah....2018 old news.

Breaking RM5 is very important. Once break all the way up to RM5.50 then RM6